<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="20959"><DrugName>AS-1403</DrugName><DrugNamesKey><Name id="42789518">TheraFab</Name></DrugNamesKey><DrugSynonyms><Name><Value>AS-1403</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TheraFab</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>yttrium-labeled muHMFG1 F(ab)2 fragment, Antisoma</Value></Name><Name><Value>90-Y-muHMFG1 F(ab)2 fragment (anticancer), Antisoma</Value></Name></DrugSynonyms><CompanyOriginator id="14239">Antisoma plc</CompanyOriginator><CompaniesSecondary><Company id="14239">Antisoma plc</Company><Company id="19446">Roche Holding AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="20959" type="Drug"><TargetEntity id="279975" type="siDrug">TheraFab</TargetEntity></SourceEntity><SourceEntity id="14239" type="Company"><TargetEntity id="4295896407" type="organizationId">Sarossa Capital Ltd</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="49">Breast tumor</Indication><Indication id="755">Lung tumor</Indication></IndicationsSecondary><ActionsSecondary><Action id="1552">Radioimmunotherapeutic</Action><Action id="55685">Anticancer monoclonal antibody</Action></ActionsSecondary><Technologies><Technology id="51">Monoclonal antibody</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="1263">Immuno-oncology</Technology></Technologies><LastModificationDate>2017-11-23T09:25:47.000Z</LastModificationDate><ChangeDateLast>2017-11-23T00:00:00.000Z</ChangeDateLast><AddedDate>1998-11-30T12:30:22.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14239" linkType="Company"&gt;Antisoma&lt;/ulink&gt;, in collaboration with &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;, was developing AS-1403 (TheraFab), an yttrium-90-labeled murine monoclonal antibody fragment (a derivative of the antibody used in pemtumomab; qv), for the potential treatment of solid tumors, including lung and breast cancer [&lt;ulink linkID="307070" linkType="reference"&gt;307070&lt;/ulink&gt;]. A phase I biodistribution study was initiated in January 2001 for the treatment of non-small-cell lung cancer (NSCLC) [&lt;ulink linkID="397168" linkType="reference"&gt;397168&lt;/ulink&gt;]. In August 2002, recruitment into the trial was completed [&lt;ulink linkID="462269" linkType="reference"&gt;462269&lt;/ulink&gt;]. In August 2003, however, development of AS-1403 was discontinued following results of the phase I biodistribution study [&lt;ulink linkID="502650" linkType="reference"&gt;502650&lt;/ulink&gt;], [&lt;ulink linkID="502725" linkType="reference"&gt;502725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The biodistribution study examined the ability of AS-1403 to deliver a targeted dose of radiation to tumors in patients with NSCLC. Radioactivity accumulated in tumors following administration, however, dosimetry findings suggested that quantities of radioactivity delivered to other tissues such as the kidneys would produce unacceptable levels of toxicity if a therapeutic isotope were used. The company therefore discontinued the development of AS-1403 [&lt;ulink linkID="502650" linkType="reference"&gt;502650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1998, AS-1403 had been expected to enter phase I/II trials in late 1999 for the treatment of lung and breast cancers [&lt;ulink linkID="307070" linkType="reference"&gt;307070&lt;/ulink&gt;], [&lt;ulink linkID="313759" linkType="reference"&gt;313759&lt;/ulink&gt;]. By January 2001, a phase I study designed to assess AS-1403's biodistribution in NSCLC was ready to enroll patients in Australia, and a number of European clinical sites had also been recruited to take part in the study during 2001 [&lt;ulink linkID="397168" linkType="reference"&gt;397168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2000, preclinical data on AS-1403 were presented at the eighth BioPartnering Conference, London, UK. Antisoma anticipated that a phase I biodistribution study in patients with lung cancer would be performed by the end of 2000 [&lt;ulink linkID="386919" linkType="reference"&gt;386919&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; AS-1403 was a radiolabeled monoclonal antibody that used the F(ab)2 fragment of the HMFG1 antibody [&lt;ulink linkID="386919" linkType="reference"&gt;386919&lt;/ulink&gt;]. Using the agent in combination with standard radiotherapy, Antisoma hoped to provide better tumor control by increasing the radiation dose at the site of the tumor without significantly increasing normal tissue damage. The antibody sought out and bound to the tumor to deliver its radioactive component, yttrium-90. The treatment protocol aimed to focus the yttrium-90 tumor-killing potential with that of the external beam radiation onto the tumor [&lt;ulink linkID="397168" linkType="reference"&gt;397168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, Antisoma granted Roche exclusive worldwide rights to AS-1403 [&lt;ulink linkID="470481" linkType="reference"&gt;470481&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-22T00:00:00.000Z</StatusDate><Source id="502650" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-22T00:00:00.000Z</StatusDate><Source id="502650" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-22T00:00:00.000Z</StatusDate><Source id="502650" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-26T00:00:00.000Z</StatusDate><Source id="502725" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-26T00:00:00.000Z</StatusDate><Source id="502725" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-26T00:00:00.000Z</StatusDate><Source id="502725" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-22T00:00:00.000Z</StatusDate><Source id="502650" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-26T00:00:00.000Z</StatusDate><Source id="502725" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-11-18T00:00:00.000Z</StatusDate><Source id="470481" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-11-18T00:00:00.000Z</StatusDate><Source id="470481" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-11-18T00:00:00.000Z</StatusDate><Source id="470481" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-11-18T00:00:00.000Z</StatusDate><Source id="470481" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-01-30T00:00:00.000Z</StatusDate><Source id="307070" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-01-30T00:00:00.000Z</StatusDate><Source id="307070" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-11-30T00:00:00.000Z</StatusDate><Source id="307070" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-11-30T00:00:00.000Z</StatusDate><Source id="307070" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=441289" linkType="reference" linkID="441289"&gt;441289&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=528597" linkType="reference" linkID="528597"&gt;528597&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14239">Antisoma plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="109919" title="Roche to develop Antisoma's oncology pipeline"></Deal></Deals><PatentFamilies><PatentFamily id="1287489" number="WO-00174905" title="Compounds for targeting"></PatentFamily><PatentFamily id="1422140" number="WO-09218534" title="Minimum recognition unit of a pem mucin tandem repeat specific monoclonal antibody."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="2">Drug Target</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Antisoma plc" id="14239"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>